Scholars@Duke
Rajan Tilak Gupta

Rajan Tilak Gupta

Professor of Radiology
Radiology, Abdominal Imaging
rajan.gupta@duke.edu
Department of Radiology, BOX_3808 Med Ctr, Durham, NC 27710

Scholarly Works - Conferences

Impact of pre-treatment MRI capsular involvement and extraprostatic extension on metastasis free and overall survival in localized prostate cancer

Conference Journal of Clinical Oncology · January 1, 2024 Background: Multiparametric magnetic resonance imaging (mpMRI) is not currently included in prostate cancer (PC) staging. The purpose of this study was to test the association between mpMRI detected prostate capsule involvement and extraprostatic extension ... Full text Cite

Association of multiparametric magnetic resonance imaging findings with oncologic outcomes in non-palpable localized prostate cancer.

Conference Journal of Clinical Oncology · January 1, 2024 Background: Multiparametric magnetic resonance imaging (mpMRI) is becoming increasingly integrated into the evaluation and medical decision making for localized prostate cancer. However, mpMRI findings have not been correlated with prostate cancer outcomes ... Full text Cite

PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).

Conference Journal of Clinical Oncology · May 20, 2021 TPS4596 Background: There is no standard adjuvant systemic therapy that increases overall survival (OS) over surgery alone for non-metastatic RCC. Anti-PD-1 nivolumab (nivo) improves OS in metastatic RCC and is well tolerated. In ... Full text Cite

Implementation and Impact of a Risk-Stratified Prostate Cancer Screening Algorithm as a Clinical Decision Support Tool in a Primary Care Network.

Conference J Gen Intern Med · January 2021 BACKGROUND: Implementation methods of risk-stratified cancer screening guidance throughout a health care system remains understudied. OBJECTIVE: Conduct a preliminary analysis of the implementation of a risk-stratified prostate cancer screening algorithm i ... Full text Link to item Cite

Aspergillus endophthalmitis : Clinical presentations and factors determining outcomes

Conference INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE · July 2019 Link to item Cite

Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).

Conference Journal of Clinical Oncology · May 20, 2019 e16079 Background: ICIs have revolutionized treatment for mRCC; however there are limited predictive biomarkers for response to ICIs. PD-L1 status is still controversial, demonstrating little predictive utility in mRCC. TMB is pr ... Full text Cite

Immune checkpoint inhibitor response in tumors with LRP1B variants.

Conference Journal of Clinical Oncology · May 20, 2019 e14291 Background: Low-density lipoprotein receptor-related protein 1B (LRP1B) is a putative tumor suppressor gene spanning > 500 kb on chromosome 2. A melanoma study previously reported enrichment of LRP1B mutations in respon ... Full text Cite

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).

Conference Journal of Clinical Oncology · May 20, 2019 2595 Background: ICIs are now standard of care for mRCC; however, there are few biomarkers to predict ICI response. Recent data from atezolizumab/bevacizumab trials in mRCC suggest tumors with high Teff Full text Cite

Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC).

Conference Journal of Clinical Oncology · May 20, 2019 e14259 Background: Immune checkpoint inhibitors (ICIs) are standard of care for mRCC and mUC patients (pts). PD-L1 status is gaining importance as a predictive biomarker, particularly for cisplatin-ineligible mUC. PD-L1 positivit ... Full text Cite

PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).

Conference Journal of Clinical Oncology · May 20, 2019 TPS4597 Background: The anti-PD-1 antibody nivo improves overall survival (OS) in metastatic RCC and is well tolerated. There is no standard adjuvant (adjuv) systemic therapy that increases OS over surgery alone for non-metastati ... Full text Cite

Cell proliferation as a biomarker for response to immune checkpoint inhibitors in highly inflamed renal cell carcinoma.

Conference Journal of Clinical Oncology · March 10, 2019 61 Background: Cell proliferation is an important marker of survival in many tumors and we hypothesized that this attribute could be related to response to immune checkpoint inhibitors in RCC. Previously we reported (SITC 2018) m ... Full text Cite

Cell proliferation as a biomarker for response to immune checkpoint inhibitors in PD-L1 negative renal cell carcinoma.

Conference Journal of Clinical Oncology · March 10, 2019 62 Background: Cell proliferation is an important marker of survival in many tumors, and we hypothesized that this attribute could be related to response to immune checkpoint inhibitors (ICIs) in RCC. Previously we reported (SITC ... Full text Cite

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).

Conference Journal of Clinical Oncology · March 10, 2019 63 Background: ICIs are now standard of care for mRCC; however, there are few biomarkers to predict ICI response. Recent data from atezolizumab/bevacizumab trials in mRCC suggest tumors with high Teff Full text Cite

Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).

Conference Journal of Clinical Oncology · March 1, 2019 589 Background: ICIs have revolutionized treatment for mRCC; however there are limited predictive biomarkers for response to ICIs. PD-L1 status is still controversial demonstrating little predictive utility in mRCC. TMB is predic ... Full text Cite

Characterization of genomic alterations as biomarkers of immune checkpoint inhibitor (ICI) response in metastatic urothelial carcinoma (mUC).

Conference Journal of Clinical Oncology · March 1, 2019 400 Background: ICIs have expanded therapeutic options for mUC patients (pts); however, biomarkers such as PD-L1 have not served as reliable predictors of treatment efficacy. High tumor mutation burden (TMB) has been previously d ... Full text Cite

Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC).

Conference Journal of Clinical Oncology · March 1, 2019 577 Background: Immune checkpoint inhibitors (ICIs) are now standard of care for mRCC and mUC patients (pts). PD-L1 status is gaining importance as a predictive biomarker, particularly for cisplatin-ineligible mUC. Four different ... Full text Cite

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).

Conference Journal of Clinical Oncology · March 1, 2019 607 Background: ICIs are now standard of care for mRCC; however, there are few biomarkers to predict ICI response. Recent data from atezolizumab/bevacizumab trials in mRCC suggest tumors with high Teff Full text Cite

Sarcopenia in bladder cancer patients is an unmodifiable outcomes predictor.

Conference Journal of Clinical Oncology · March 1, 2019 480 Background: Sarcopenia, a severe loss of skeletal muscle mass, predicts poor outcomes in bladder cancer (BC). But, why sarcopenia occurs in BC is unknown. Our objective was to assess if diet and physical activity were the pri ... Full text Cite

PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).

Conference Journal of Clinical Oncology · March 1, 2019 TPS684 Background: The anti-PD-1 antibody nivo improves overall survival in metastatic RCC and is well tolerated. There is no standard adjuvant systemic therapy that increases overall survival (OS) over surgery alone for non-meta ... Full text Cite

A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).

Conference Journal of Clinical Oncology · February 20, 2018 TPS710 Background: The anti-PD-1 antibody nivolumab (nivo) improves overall survival (OS) in metastatic treatment refractory RCC and is generally tolerable. In 2017, there is no standard adjuvant therapy proven to increase OS ove ... Full text Cite

Correlation Between 3D ARFI and Quantitative Imaging Metrics from SWEI and Multi-Parametric MRI in Vivo in Normal and Cancerous Prostate Tissue

Conference IEEE International Ultrasonics Symposium Ius · January 1, 2018 Prostate lesions and healthy regions from 12 radical prostatectomy patients were identified in acoustic radiation force impulse (ARFI) imaging, shear wave elasticity imaging (SWEI), and multi-parametric magnetic resonance imaging (mpMRI) apparent diffusion ... Full text Cite

Development of Fiber Optic Sensors for Leak Detection in Underground Energy Storage Pipelines

Conference 2018 6TH EDITION OF INTERNATIONAL CONFERENCE ON WIRELESS NETWORKS & EMBEDDED SYSTEMS (WECON) · 2018 Link to item Cite

A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).

Conference Journal of Clinical Oncology · May 20, 2017 TPS4596 Background: The anti-PD-1 antibody nivolumab (nivo) improves overall survival (OS) in metastatic treatment refractory RCC and is generally tolerable. In 2017, there is no standard adjuvant therapy proven to increase OS ov ... Full text Cite

Association of neuroendocrine phenotype with platinum chemotherapy outcomes in men with metastatic prostate cancer.

Conference Journal of Clinical Oncology · May 20, 2017 e16532 Background: DNA repair defects are common in men with mCRPC, and platinum chemotherapy may have a role in selected patients. We aimed to determine whether neuroendocrine variant prostate cancer (NEPC) is associated with a ... Full text Cite

Comparison between 3D ARFI imaging and mpMRI in detecting clinically-significant prostate cancer lesions

Conference IEEE International Ultrasonics Symposium Ius · November 1, 2016 Current prostate cancer screening methods involve non-targeted needle biopsies and detection of clinically-insignificant lesions that receive excessive treatments, exposing patients to unnecessary adverse side effects and placing a burden on our health car ... Full text Cite

Voltage Level Increment by Proposed Sub-Cell for Existing Topologies

Conference 2014 IEEE INNOVATIVE SMART GRID TECHNOLOGIES - ASIA (ISGT ASIA) · 2014 Link to item Cite

Methodology to register prostate B-mode and ARFI images to MR and histology

Conference IEEE International Ultrasonics Symposium Ius · December 1, 2011 Acoustic Radiation Force Impulse (ARFI) imaging is being developed for guiding needle biopsy and focal therapy of Prostate cancer (PCa). In vivo ARFI images portray internal structures in the prostate with higher contrast than matched B-mode images. Given ... Full text Cite

MRI of the Hepatobiliary System with a Liver-Specific Contrast Agent

Conference AMERICAN JOURNAL OF ROENTGENOLOGY · May 2009 Link to item Cite